In mid October, the FDA convened a special meeting of drug safety and psycho-pharmacology experts to look at whether or not the smoking cessation drug Chantix needed to continue to carry a black box warning. […]
Here’s the third installment of the saga about PR tactics on the “female sexual dysfunction” front as we get closer to the October 27/28 meeting on FSD and Patient-focused drug development. I (L.T.) first wrote […]
Please use the navigation to move within this section.